MULTIMEDICA SPA

Their core work

MultiMedica is an Italian private hospital and clinical research group based in Milan, operating across multiple hospital sites. They contribute clinical expertise and patient cohorts to European research projects focused on chronic disease, particularly diabetes and cardiovascular disease. Their work bridges clinical care with translational research, providing real-world patient data and clinical validation for multi-center studies on disease mechanisms and prevention strategies.

What they specialise in

How they've shifted over time

MultiMedica's H2020 journey began in 2017 with involvement in clinical research training (BITRECS), suggesting an early investment in building research capacity and hosting visiting clinician-scientists. From 2020 onward, they shifted decisively into disease-focused clinical research, joining two major health projects on diabetes-related neurodegeneration (RECOGNISED) and coronary heart disease prevention (CoroPrevention). This evolution shows a move from capacity-building to active participation in large-scale clinical studies on chronic disease.

MultiMedica is positioning itself as a clinical partner for large European studies on cardiometabolic disease and personalised prevention, making them a strong candidate for future projects needing Italian hospital sites and patient cohorts.

How they like to work

MultiMedica has never coordinated an H2020 project, consistently joining as a participant or third party — a profile typical of clinical sites that contribute patient access and clinical expertise rather than driving project design. With 69 unique partners across 18 countries, they operate in large, well-connected consortia. This suggests they are a reliable clinical contributor who integrates well into multinational teams without seeking the administrative burden of coordination.

Despite only 3 projects, MultiMedica has collaborated with 69 unique partners across 18 countries, reflecting participation in large multi-center clinical consortia with broad European coverage.

What sets them apart

MultiMedica combines the resources of a major private hospital group with active participation in EU-funded clinical research — a relatively rare profile among Italian private healthcare providers in H2020. Their dual focus on diabetes-neurodegeneration links and cardiovascular prevention gives them cross-disease expertise that few single clinical sites can offer. For consortium builders, they bring Italian patient populations, clinical infrastructure, and experience operating within large multi-site European studies.

Highlights from their portfolio

• CoroPrevention
  Largest funding (EUR 762,939) and longest-running project (to 2026), focused on personalised coronary heart disease prevention using biomarkers and lifestyle interventions.
• RECOGNISED
  Investigates the underexplored link between type 2 diabetes, retinal damage, and cognitive decline — an interdisciplinary question spanning endocrinology, ophthalmology, and neurology.